Evidence map›Paper›PMID 37095859›Full record

ArticleiScience2023

The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein.

Charles Zou, Hojong Yoon, Paul M C Park, J J Patten, Jesse Pellman, Jeannie Carreiro, Jonathan M Tsai, Yen-Der Li, Shourya S Roy Burman, Katherine A Donovan and 7 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Targeted protein degradation: from mechanisms to clinic.Nature reviews. Molecular cell biology · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Charles ZouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Hojong YoonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Paul M C ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
J J PattenDepartment of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA 02118, USA.
Jesse PellmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jeannie CarreiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jonathan M TsaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yen-Der LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Shourya S Roy BurmanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jessica GasserDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Adam S SperlingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Radosław P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Robert A DaveyDepartment of Microbiology, Boston University School of Medicine and NEIDL, Boston University, Boston, MA 02118, USA.
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Mikołaj SłabickiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Dana-Farber Cancer Institute · USBroad Institute · USBoston University · USHarvard University · US

Funding

Defining mechanisms of thalidomide analog resistanceK08CA252174 · NCI · DANA-FARBER CANCER INST · PI SPERLING, ADAM · 2020 to 2024
$1.3M
Expanding pharmacological modalities for targeted cancer therapyK00CA253754 · NCI · BROAD INSTITUTE, INC. · PI YOON, HOJONG · 2021 to 2023
$292k
NCI NIH HHS K00 CA253754NCI NIH HHS K08 CA252174
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hijacks multiple human proteins during infection and viral replication. To examine whether any viral proteins employ human E3 ubiquitin ligases, we evaluated the stability of SARS-CoV-2 proteins with inhibition of the ubiquitin proteasome pathway. Using genetic screens to dissect the molecular machinery involved in the degradation of candidate viral proteins, we identified human E3 ligase RNF185 as a regulator of protein stability for the SARS-CoV-2 envelope protein. We found that RNF185 and the SARS-CoV-2 envelope co-localize to the endoplasmic reticulum (ER). Finally, we demonstrate that the depletion of RNF185 significantly increases SARS-CoV-2 viral titer in a cellular model. Modulation of this interaction could provide opportunities for novel antiviral therapies.

Indexed as

Cell biologyVirology

Identifiers

PMID37095859
PMCPMC10082641
OpenAlexW4362723136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.